FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381664493> ?p ?o ?g. }

• W4381664493 abstract "Background Infections caused by carbapenem-resistant Pseudomonas aeruginosa (CRPA) are related to higher mortality. The objective of this study was to explore clinical outcomes of CRPA bacteremia, identify risk factors and also, compare the efficacy of traditional and novel antibiotic regimens. Methods This retrospective study was conducted at a blood diseases hospital in China. The study included hematological patients who were diagnosed with CRPA bacteremia between January 2014 and August 2022. The primary endpoint was all-cause mortality at day 30. Secondary endpoints included 7-day and 30-day clinical cure. Multivariable Cox regression analysis was employed to identify mortality-related risk factors. Results 100 patients infected with CRPA bacteremia were included and 29 patients accepted allogenic-hematopoietic stem cell transplantation. 24 received ceftazidime-avibactam (CAZ-AVI)-based therapy and 76 received other traditional antibiotics. 30-day mortality was 21.0%. Multivariable cox regression analysis showed neutropenia &gt;7 days after bloodstream infections (BSI) (P=0.030, HR: 4.068, 95%CI: 1.146~14.434), higher Pitt bacteremia score (P&lt;0.001, HR:1.824, 95%CI: 1.322~2.517), higher Charlson comorbidity index (P=0.01, HR: 1.613, 95%CI: 1.124~2.315) and bacteremia due to multidrug-resistant Pseudomonas aeruginosa (MDR-PA) (P=0.024, HR:3.086, 95%CI: 1.163~8.197) were identified as independent risk factors of 30-day mortality. After controlling for confounders, an additional multivariable cox regression analysis revealed definitive regimens containing CAZ-AVI were associated with lower mortality in CRPA bacteremia (P=0.016, HR: 0.150, 95%CI: 0.032~0.702), as well as in MDR-PA bacteremia (P=0.019, HR: 0.119, 95%CI: 0.020~0.709). Conclusions For patients with hematological diseases and CRPA bacteremia, 30-day mortality rate was 21.0% (21/100). Neutropenia &gt;7 days after BSI, higher Pitt bacteremia score, higher Charlson comorbidity index and bacteremia due to MDR-PA increased 30-day mortality. CAZ-AVI-based regimens were effective alternatives for bacteremia due to CRPA or MDR-PA." @default.
• W4381664493 created "2023-06-23" @default.
• W4381664493 creator A5003460402 @default.
• W4381664493 creator A5011020214 @default.
• W4381664493 creator A5020924929 @default.
• W4381664493 creator A5022637765 @default.
• W4381664493 creator A5029862222 @default.
• W4381664493 creator A5054833896 @default.
• W4381664493 creator A5056433537 @default.
• W4381664493 creator A5065595626 @default.
• W4381664493 creator A5071839004 @default.
• W4381664493 creator A5076815382 @default.
• W4381664493 creator A5078809929 @default.
• W4381664493 creator A5086102477 @default.
• W4381664493 creator A5086214965 @default.
• W4381664493 date "2023-06-21" @default.
• W4381664493 modified "2023-09-26" @default.
• W4381664493 title "Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa in patients with hematological diseases" @default.
• W4381664493 cites W1996903151 @default.
• W4381664493 cites W2005037961 @default.
• W4381664493 cites W2015984063 @default.
• W4381664493 cites W2024263059 @default.
• W4381664493 cites W2024595881 @default.
• W4381664493 cites W2027225993 @default.
• W4381664493 cites W2054363434 @default.
• W4381664493 cites W2075287054 @default.
• W4381664493 cites W2092491526 @default.
• W4381664493 cites W2103121782 @default.
• W4381664493 cites W2113319277 @default.
• W4381664493 cites W2131948745 @default.
• W4381664493 cites W2137194557 @default.
• W4381664493 cites W2142343447 @default.
• W4381664493 cites W2143172705 @default.
• W4381664493 cites W2156404545 @default.
• W4381664493 cites W2303008909 @default.
• W4381664493 cites W2435544242 @default.
• W4381664493 cites W2550317740 @default.
• W4381664493 cites W2741262638 @default.
• W4381664493 cites W2776093380 @default.
• W4381664493 cites W2883234304 @default.
• W4381664493 cites W2905421775 @default.
• W4381664493 cites W2947248407 @default.
• W4381664493 cites W2960481524 @default.
• W4381664493 cites W2990143720 @default.
• W4381664493 cites W2991949326 @default.
• W4381664493 cites W3042253385 @default.
• W4381664493 cites W3094338265 @default.
• W4381664493 cites W3114918623 @default.
• W4381664493 cites W3214996026 @default.
• W4381664493 cites W4205774220 @default.
• W4381664493 cites W4214922586 @default.
• W4381664493 cites W4224946899 @default.
• W4381664493 cites W4226305437 @default.
• W4381664493 cites W4229924182 @default.
• W4381664493 cites W4294541121 @default.
• W4381664493 cites W4319661295 @default.
• W4381664493 doi "https://doi.org/10.3389/fcimb.2023.1156651" @default.
• W4381664493 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37415825" @default.
• W4381664493 hasPublicationYear "2023" @default.
• W4381664493 type Work @default.
• W4381664493 citedByCount "0" @default.
• W4381664493 crossrefType "journal-article" @default.
• W4381664493 hasAuthorship W4381664493A5003460402 @default.
• W4381664493 hasAuthorship W4381664493A5011020214 @default.
• W4381664493 hasAuthorship W4381664493A5020924929 @default.
• W4381664493 hasAuthorship W4381664493A5022637765 @default.
• W4381664493 hasAuthorship W4381664493A5029862222 @default.
• W4381664493 hasAuthorship W4381664493A5054833896 @default.
• W4381664493 hasAuthorship W4381664493A5056433537 @default.
• W4381664493 hasAuthorship W4381664493A5065595626 @default.
• W4381664493 hasAuthorship W4381664493A5071839004 @default.
• W4381664493 hasAuthorship W4381664493A5076815382 @default.
• W4381664493 hasAuthorship W4381664493A5078809929 @default.
• W4381664493 hasAuthorship W4381664493A5086102477 @default.
• W4381664493 hasAuthorship W4381664493A5086214965 @default.
• W4381664493 hasBestOaLocation W43816644931 @default.
• W4381664493 hasConcept C126322002 @default.
• W4381664493 hasConcept C177713679 @default.
• W4381664493 hasConcept C2776685102 @default.
• W4381664493 hasConcept C2776694085 @default.
• W4381664493 hasConcept C2777063308 @default.
• W4381664493 hasConcept C2777637488 @default.
• W4381664493 hasConcept C2779443120 @default.
• W4381664493 hasConcept C501593827 @default.
• W4381664493 hasConcept C50382708 @default.
• W4381664493 hasConcept C523546767 @default.
• W4381664493 hasConcept C54355233 @default.
• W4381664493 hasConcept C71924100 @default.
• W4381664493 hasConcept C86803240 @default.
• W4381664493 hasConcept C89423630 @default.
• W4381664493 hasConceptScore W4381664493C126322002 @default.
• W4381664493 hasConceptScore W4381664493C177713679 @default.
• W4381664493 hasConceptScore W4381664493C2776685102 @default.
• W4381664493 hasConceptScore W4381664493C2776694085 @default.
• W4381664493 hasConceptScore W4381664493C2777063308 @default.
• W4381664493 hasConceptScore W4381664493C2777637488 @default.
• W4381664493 hasConceptScore W4381664493C2779443120 @default.
• W4381664493 hasConceptScore W4381664493C501593827 @default.
• W4381664493 hasConceptScore W4381664493C50382708 @default.
• W4381664493 hasConceptScore W4381664493C523546767 @default.

• next